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San Camillo and Forlanini Hospitals, Department of Medical Oncology, Rome, ItalyIn the European Union there are some 84,400 new cases of
kidney cancer with 34,700 deaths yearly [1]. With increasing
knowledge of the mechanisms that drive renal cancer biology
and the development of agents that target angiogenesis,
growth and metastases, hope has been given to patients with
this disease. Enormous progress has been made in the last
few years for patients with advanced and metastatic renal cell
cancer (RCC). Since the era of cytokine therapy, overall sur-
vival has now doubled, with the approval of many new agents
targeting cell signalling pathways.
Six agents which target either the vascular endothelial
growth factor (VEGF) pathway or the mammalian target of
rapamycin (mTOR) pathway have been developed and ap-
proved for use in advanced and metastatic RCC. Increasing
knowledge of how to actively manage the side effects of these
agents has also greatly added to improving survival. In addi-
tion, the realistic hope of novel treatments – such as novel
immunotherapy (anti-programmed cell death protein 1 (PD-
1), anti-programmed cell death 1 ligand (PD-1L) and inhibition
of fibroblast growth factor receptor (FGFR) – may also add to
our therapeutic armamentarium.
Improvements in surgical techniques have likewise been
important. Notably, cytoreductive nephrectomy remains the
standard of care as compared with drug treatment alone,
although trials addressing this question are ongoing. Metasta-
sectomy has become common practice, as local therapy of
metastases can often be integral to the treatment ofmetastatic RCC. Surgical resection has traditionally been the
preferred approach to metastasectomy, but recent data on
stereotactic radiosurgery (SRS) indicate that this treatment
modality is a valuable non-invasive alternative. Definite
guidelines for surgery of metastatic lesions do not exist, but
recommendations can be made. The available evidence for
common metastatic sites will be reviewed, including metasta-
sectomy following targeted therapy and non-invasive
approaches such as SRS.
This educational section comprises four excellent presen-
tations that review factors which guide treatment selection,
the algorithm for advanced RCC from first- to third-line ther-
apies, proper sequencing, novel immunotherapy and details
of how therapy may be individualised and surgery integrated
in the optimal approach for renal cancer.
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